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Background: Despite the high efficacy of dabigatran in the treatment of venous thromboembolism (VTE), this drug is still not approved for VTE in 
the US. There are a subgroup of patients with refractoriness to warfarin who are placed on parenteral anticoagulation. This approach is expensive 
and uncomfortable. The role of dabigatran in this setting has not been evaluated.
Methods: 42 patients with VTE refractory to warfarin were placed on dabigatran. The dose was 150 mg and 75 mg twice daily in 27 and 15 
patients respectively. There were 5 patients with pulmonary embolism (PE), 17 with deep venous thrombosis (DVT) and 20 with both. Refractoriness 
was defined as recurrent VTE on therapeutic warfarin. Evaluation for thrombophilia was obtained in 36 patients.
Results: The mean follow up was 7±1.5 months. There were no VTE or major bleeding during this time. Two patients could not tolerate dabigatran 
due to gastrointestinal side effects. A thrombophilic state was found in 14 patients.
Conclusions: Thrombophilia is found in a large minority of patients with refractoriness to warfarin. Dabigatran provides an effective and safe 
treatment alternative in these patients.
